NEW DELHI: , where ace investor Rakesh Jhunjhunwala owns over Rs 700 crore worth of stake, has delivered ‘optically’ good numbers for June quarter, led by one-off income, but analysts said the drugmakers operating performance disappointed them. Price targets…
